Trials
Search / Trial NCT06439173

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Launched by INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA · May 31, 2024

Trial Information

Current as of February 12, 2025

Recruiting

Keywords

Lymphoma B Cell Car T Therapy Cytopenia Hematopoietic Niche Inflammation

ClinConnect Summary

This clinical trial is studying how inflammation affects the bone marrow and blood cell production in patients with diffuse large B-cell lymphoma who have undergone CAR-T cell therapy. CAR-T therapy is a type of immunotherapy that helps the body fight cancer, but some patients experience a drop in blood cell counts, known as cytopenias, after treatment. This trial aims to understand why these cytopenias occur and to explore potential therapies that could help repair the bone marrow environment and improve blood cell production.

To participate in this study, patients must be over 18 years old and currently receiving CAR-T therapy for diffuse large B-cell lymphoma. They will undergo various tests and analyses to evaluate their bone marrow and inflammatory status. The researchers will also test new therapies that may help improve their condition. This trial is currently recruiting participants, and those who join can expect to contribute to important research that could lead to better treatments for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy
  • Over 18 years old
  • Sign the informed consent
  • Exclusion Criteria:
  • Under 18 years old
  • Do not sign the informed consent

About Instituto De Investigación Biomédica De Salamanca

The Instituto de Investigación Biomédica de Salamanca (IBSAL) is a leading biomedical research institution dedicated to advancing healthcare through innovative scientific inquiry and clinical trials. Situated in Salamanca, Spain, IBSAL fosters collaboration among researchers, healthcare professionals, and academic institutions to facilitate cutting-edge research in various medical fields. With a strong emphasis on translational medicine, IBSAL aims to bridge the gap between laboratory discoveries and clinical applications, ultimately enhancing patient care and treatment outcomes. The institute adheres to the highest ethical standards and regulatory compliance, ensuring the integrity and reliability of its research endeavors.

Locations

Salamanca, , Spain

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0